Heron Therapeutics (HRTX) Stock Price, News & Analysis

Company Overview

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.39 to $1.47
• 50-Day Range: $1.28 to $2.23
• 52-Week Range: $1.04 to $2.68
• Volume: 625,571 shs
• Average Volume: 1.66 million shs
• Market Capitalization: $212.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

Heron Therapeutics Stock Analysis - MarketRank™

Heron Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 235th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Heron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Heron Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Heron Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Heron Therapeutics is -65.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Heron Therapeutics is -65.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.04% of the outstanding shares of Heron Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Heron Therapeutics has a short interest ratio ("days to cover") of 23.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Heron Therapeutics has recently decreased by 4.33%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Heron Therapeutics does not currently pay a dividend.

Dividend Growth

Heron Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.96

Percentage of Shares Shorted

23.04% of the outstanding shares of Heron Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Heron Therapeutics has a short interest ratio ("days to cover") of 23.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Heron Therapeutics has recently decreased by 4.33%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.20

News Sentiment

Heron Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Heron Therapeutics this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

3 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Heron Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,230,656.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.86% of the stock of Heron Therapeutics is held by insiders.

Percentage Held by Institutions

80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HRTX Stock Analysis - Frequently Asked Questions

How have HRTX shares performed this year?

Heron Therapeutics' stock was trading at $1.53 at the beginning of 2025. Since then, HRTX stock has decreased by 14.4% and is now trading at $1.31.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its earnings results on Friday, August, 8th. The biotechnology company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. The biotechnology company earned $37.20 million during the quarter, compared to analysts' expectations of $38.08 million.
Read the conference call transcript.

Does Heron Therapeutics have any subsidiaries?

Heron Therapeutics subsidiaries include these companies: Heron Therapeutics B.V..

Who are Heron Therapeutics' major shareholders?

Top institutional investors of Heron Therapeutics include Geode Capital Management LLC (2.34%), AIGH Capital Management LLC (1.97%), Congress Park Capital LLC (1.49%) and Monaco Asset Management SAM (0.71%). Insiders that own company stock include Rubric Capital Management Lp, Adam Morgan, Craig A Collard, Ira Duarte and William P Forbes.
View institutional ownership trends.

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HRTX
• CIK: 818033
• Web: www.herontx.com
• Phone: (858) 251-4400
• Fax: 650-365-6490
• Employees: 300
• Year Founded: 1983

Price Target and Rating

• Average Price Target for Heron Therapeutics: $4.50
• High Price Target: $6.00
• Low Price Target: $3.00
• Potential Upside/Downside: +224.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.58 million
• Net Margins: -0.62%
• Pretax Margin: -0.62%
• Return on Equity: N/A
• Return on Assets: -0.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.82
• Quick Ratio: 1.76

Sales & Book Value

• Annual Sales: $144.29 million
• Price / Sales: 1.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.18) per share
• Price / Book: -7.69

Miscellaneous

• Outstanding Shares: 153,290,000
• Free Float: 143,624,000
• Market Cap: $212.31 million
• Optionable: Optionable
• Beta: 1.15